Metrnl：心血管和代谢疾病有前景的生物标志物和治疗靶点。
Metrnl: a promising biomarker and therapeutic target for cardiovascular and metabolic diseases.
机构信息
Department of Geriatrics, Hubei Key Laboratory of Metabolic and Chronic Diseases, Renmin Hospital of Wuhan University, Wuhan University at Jiefang Road 238, Wuhan, 430060, China.
Department of Ultrasound, Union Hospital, Tongji Medical College, Clinical Research Center for Medical Imaging in Hubei Province, Hubei Province Key Laboratory of Molecular Imaging, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China.
出版信息
Cell Commun Signal. 2024 Aug 5;22(1):389. doi: 10.1186/s12964-024-01767-8.
Modern human society is burdened with the pandemic of cardiovascular and metabolic diseases. Metrnl is a widely distributed secreted protein in the body, involved in regulating glucose and lipid metabolism and maintaining cardiovascular system homeostasis. In this review, we present the predictive and therapeutic roles of Metrnl in various cardiovascular and metabolic diseases, including atherosclerosis, ischemic heart disease, cardiac remodeling, heart failure, hypertension, chemotherapy-induced myocardial injury, diabetes mellitus, and obesity.
现代人类社会背负着心血管和代谢疾病的流行。Metrnl 是一种广泛分布于体内的分泌蛋白，参与调节葡萄糖和脂质代谢，维持心血管系统的内稳态。在这篇综述中，我们介绍了 Metrnl 在各种心血管和代谢疾病中的预测和治疗作用，包括动脉粥样硬化、缺血性心脏病、心肌重构、心力衰竭、高血压、化疗诱导的心肌损伤、糖尿病和肥胖症。
Zotero 插件